Quantum BioPharma Ltd. Advances MS Treatment with CDMO Agreement for Lucid-MS

Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) has announced a pivotal development in its quest to address multiple sclerosis (MS) through its subsidiary, Huge Biopharma Australia Pty Ltd. The company has entered into a contract development and manufacturing organization (CDMO) agreement to produce an oral formulation of Lucid-MS for an upcoming Phase 2 clinical trial. This trial aims to assess the efficacy of Lucid-MS in restoring mobility in individuals with MS, a condition that affects millions worldwide. The therapy has shown promise in preclinical studies, enabling animals to regain walking ability, marking a potential breakthrough in MS treatment.

Lucid-MS represents a novel approach to treating MS, being a patented, first-in-class, non-immunomodulatory neuroprotective compound. Its ability to prevent demyelination, a critical factor in MS and other neurodegenerative diseases, has been demonstrated in preclinical models. The CDMO agreement is a crucial milestone towards submitting an Investigational New Drug application to the FDA for Lucid-21-302 in MS, bringing hope to those affected by this debilitating condition.

For further details on this development, visit https://ibn.fm/y8RRY. Quantum BioPharma's commitment to innovative treatments for neurodegenerative and metabolic disorders is evident in its portfolio, which includes Lucid-MS among other promising candidates. The company's strategic investments and partnerships, such as the one with Unbuzzd Wellness Inc., underscore its dedication to advancing healthcare solutions.

The significance of this announcement lies not only in the potential of Lucid-MS to transform MS treatment but also in the broader implications for neurodegenerative disease research. Quantum BioPharma's progress underscores the importance of continued investment and innovation in biopharmaceuticals to address unmet medical needs. For more information on Quantum BioPharma and its initiatives, visit https://ibn.fm/QNTM.